

CLINICAL TRIALS AND OBSERVATIONS

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin,¹ Ju-Whei Lee,² Hugo F. Fernandez,³ Omar Abdel-Wahab,^{4,5} John M. Bennett,⁶ Rhett P. Ketterling,⁷ Hillard M. Lazarus,⁸ Ross L. Levine,^{4,5} Mark R. Litzow,⁹ Elisabeth M. Paietta,¹⁰ Jay P. Patel,⁴ Janis Racevskis,¹⁰ Jacob M. Rowe,¹¹ Martin S. Tallman,⁵ Zhuoxin Sun,² and Selina M. Luger¹

¹Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; ²Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA; ³Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL; ⁴Human Oncology and Pathogenesis Program, and ⁵Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; ⁶Department of Pathology, University of Rochester, Rochester, NY; ⁷Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ⁸Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; ⁹Department of Hematology, Mayo Clinic, Rochester, MN; ¹⁰Department of Oncology, Montefiore Medical Center, Bronx, NY; and ¹¹Rambam Medical Center, Haifa, Israel

Key Points

- High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with *FLT3*-ITD, *NPM1*, and *DNMT3A* mutations.
- High-dose daunorubicin is required for the favorable impact of the *NPM1* mutation in AML.

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m²) improved overall survival in adults <60 years old with acute myeloid leukemia (AML); however, at initial analysis, the benefit was restricted to younger patients (<50 years) and patients without unfavorable cytogenetics or a *FLT3*-ITD mutation. Here, we update the results of E1900 after longer follow-up (median, 80.1 months among survivors), focusing on the benefit of HD daunorubicin on common genetic subgroups. Compared with standard-dose daunorubicin (45 mg/m²), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 ($P = .001$). Younger patients (<50 years) benefited from HD daunorubicin (HR, 0.66; $P = .002$), as did patients with favorable and intermediate cytogenetics (HR, 0.51; $P = .03$ and HR, 0.68; $P = .01$, respectively). Patients with unfavorable cytogenetics were shown to benefit from HD daunorubicin on multivariable analysis (adjusted HR, 0.66; $P = .04$). Patients with *FLT3*-ITD (24%), *DNMT3A* (24%), and *NPM1* (26%) mutant AML all benefited from HD daunorubicin (HR, 0.61, $P = .009$; HR, 0.62, $P = .02$; and HR, 0.50, $P = .002$; respectively). HD benefit was seen in the subgroup of older patients (50–60 years) with the *FLT3*-ITD or *NPM1* mutation. Additionally, the presence of an *NPM1* mutation confers a favorable prognosis only for patients receiving anthracycline dose intensification during induction. (*Blood*. 2016;127(12):1551-1558)

Introduction

The outcome of patients with acute myeloid leukemia (AML) is varied and impacted by patient and disease characteristics and therapy. The combination of anthracycline plus cytarabine has been a common intensive induction regimen for patients with AML for decades.^{1,2} Unfortunately, there has been little improvement in this treatment since it was developed. Although the addition of gemtuzumab ozogamicin and cladribine to an anthracycline plus cytarabine doublet has recently been shown to improve overall survival (OS) in patients with favorable and unfavorable cytogenetics, respectively,^{3,4} and high-dose (HD) cytarabine may improve OS in young patients,⁵ most attempts to improve OS have failed.⁶⁻¹² Whether anthracycline intensification during induction can improve OS in de novo AML was a question addressed by the Eastern Cooperative Oncology Group–American

College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group study E1900.¹³⁻¹⁶

E1900 enrolled patients ≤ 60 years of age with de novo untreated AML and randomized them to standard dose (SD, 45 mg/m²) or HD (90 mg/m²) daunorubicin for 3 days in combination with cytarabine. Reported in 2009 after a median of 25.2 months of follow-up among survivors, the E1900 trial demonstrated that HD daunorubicin was associated with an increased rate of complete remission (CR) and an OS benefit. Subgroup analyses showed that HD daunorubicin benefited those with age <50 years, those with intermediate cytogenetics, and those with *FLT3*-ITD–negative AML; however, no benefit was demonstrated in higher-risk subgroups including patients ≥ 50 years, those with unfavorable cytogenetics, and those with *FLT3*-ITD mutations.¹⁷

Submitted July 10, 2015; accepted January 4, 2016. Prepublished online as *Blood* First Edition paper, January 11, 2016; DOI 10.1182/blood-2015-07-657403.

Presented in abstract form at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2016 by The American Society of Hematology

Since the report of E1900 in 2009, the prognostic impact of a series of recurrent gene mutations in AML have been defined.^{18,19} Patel et al¹⁸ explored the impact of daunorubicin dose on AML molecular subgroups and reported a benefit of HD daunorubicin in patients with *DNMT3A* mutations. Here we update the results of E1900 with longer follow-up and demonstrate the benefit of HD daunorubicin in an expanded group of AML patients.

Methods

Patients

Between December 2002 and November 2008, 657 patients between the ages of 17 and 60 years with de novo untreated AML were enrolled on ECOG-ACRIN Cancer Research Group study E1900 (#NCT00049517) as detailed in Fernandez et al.¹⁷ Cytogenetic risk assignment was according to Slovak et al.²⁰ Patients were classified as indeterminate risk if they had unknown cytogenetic risk as per Slovak et al or lacked sufficient data for classification. Testing for presence of an FMS-like tyrosine kinase internal tandem duplication (*FLT3*-ITD) and mixed-lineage leukemia partial tandem duplication (*MLL*-PTD) was conducted centrally as previously described.^{17,21-23} Sequencing of *NPM1*, *DNMT3A*, *IDH1/2*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *KIT*, *RUNX1*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, and *TP53* was later conducted on banked samples as described by Patel et al.¹⁸ *FLT3*-ITD allelic ratio was not available. The median follow-up time from the patients still alive and included in the current analysis, calculated from the time of randomization for induction therapy, was 80.1 months (range, 0.8-120.4 months). In total, 25 (4%) patients were lost to follow-up.

Treatment

Eligible patients were randomly assigned to either an SD (45 mg/m²) or HD (90 mg/m²) of daunorubicin for 3 days in combination with 7 days of continuously infused cytarabine at 100 mg/m² per day. A second cycle of the same drugs with daunorubicin at 45 mg/m² per day was administered to patients in either study arm if the nadir bone marrow biopsy demonstrated residual leukemia. Patients who achieved CR proceeded to consolidation with assignment to autologous or allogeneic hematopoietic stem cell transplant (HCT) based on risk of relapse as predicted by cytogenetic risk²⁰ and white blood cell count at presentation. Patients assigned to autologous HCT were randomized to receive or not receive a single dose of gemtuzumab ozogamicin (GO) at 6 mg/m² after stem cell collection but prior to autologous transplant. Genetic mutations were not used to determine induction or consolidation therapy allocation. Further details of the regimens and eligibility have been previously described.^{17,23}

Statistical methods

OS was measured from induction randomization to death from any cause (censored at last contact) for evaluating the induction effect. For evaluating the GO effect, OS was defined from consolidation randomization to death from any cause (censored at last contact). Event-free survival (EFS) was measured from randomization to completion of protocol induction chemotherapy without documentation of CR, relapse after CR, or death from any cause (censored at last contact). The analysis was performed on the intention-to-treat principle. Time-to-event distributions were estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs; HD vs SD) for the target events were computed and tested for significance using univariate and multivariable Cox proportional hazards (PH) models. Multivariable Cox PH models were adjusted for sex, age, hemoglobin level, leukocyte count, platelet count, and cytogenetic profile (with age, hemoglobin level, leukocyte count, and platelet count considered continuous variables). When OS was compared between the GO and the no GO groups, stratified (by induction treatment) log-rank tests and stratified Cox PH models were used instead. A secondary analysis on the GO effect (actually received vs not received) was further conducted based on patients who actually received the autologous HCT and the OS compared was measured

from the time of autologous HCT. Four-year cumulative relapse rates were computed using the statistical software R, *cmprsk* package, taking into account death without relapse as a competing event.²⁴ The relapse time was measured from the onset of CR.

To explore the induction treatment effect on subgroups, the above analysis methods were performed with no statistical adjustment for multiple testing. Given the rarity of subsequent allogeneic stem cell transplant on the E1900 enrolled patients (17 randomized to SD daunorubicin, 19 randomized to HD daunorubicin), no further analysis was conducted to address the possible confounding effect of subsequent allogeneic transplant on induction treatment effect. All reported *P* values are 2 sided.

Results

Overall survival

In total, 657 patients were enrolled in E1900 and were followed for OS. The characteristics of patients at study entry have been previously described.¹⁷ For all patients, the HR for death in the HD group, compared with the SD group, was 0.74 (95% confidence interval [CI], 0.61-0.89; Wald *P* = .001; Table 1). To confirm this benefit, a multivariable Cox PH model was used to examine the impact of HD daunorubicin with adjustment for sex, age, cytogenetics, hemoglobin level, leukocyte count, and platelet count. With adjustment, the HR for death in the HD group remained at 0.74 (95% CI, 0.61-0.89; Wald *P* = .001). The median OS was 16.6 vs 25.4 months in the SD and HD groups, respectively (log-rank *P* = .001; Table 1).

Effect of age: HD daunorubicin benefits age <50

The median age of all patients was 48 years (range, 17-60 years) with 45.2% ≥50 years. For patients <50 years, the HR for death in the HD group was 0.66 (95% CI, 0.50-0.85; Wald *P* = .002; Table 1), with a median OS of 44.7 vs 20.7 months in the SD group (log-rank *P* = .002; supplemental Figure 1 available on the *Blood* Web site). In contrast, for patients aged ≥50 years, a significant benefit of HD daunorubicin was not confirmed (HR, 0.81; 95% CI, 0.62-1.06; Wald *P* = .12; supplemental Figure 1). Results were similar on multivariable analysis (Table 1).

Effect of cytogenetic profile: HD daunorubicin benefits patients with favorable and intermediate cytogenetic risk

Pretreatment cytogenetics showed 13.6% having favorable, 40.9% having intermediate, 18.6% having unfavorable, and 26.9% having indeterminate risk. On univariate analysis, HD daunorubicin benefited patients with either favorable or intermediate cytogenetics (supplemental Figure 2). In the favorable-risk group, the rate of CR was not different, but superior OS was seen in patients assigned to HD daunorubicin: median OS not reached compared with 39.4 months in the SD group (HR for death, 0.51; 95% CI, 0.28-0.93; Wald *P* = .03; Table 1). In the intermediate-risk group, HD daunorubicin led to both an improved CR rate and increased OS: median OS was 33.5 months for the HD group vs 20.1 months for SD (HR for death, 0.68; 95% CI, 0.50-0.92; Wald *P* = .01). On univariate analysis, neither an improvement in CR rate nor a survival benefit could be confirmed in the indeterminate (HR, 0.88; 95% CI, 0.62-1.24; Wald *P* = .47) and unfavorable-risk group (HR, 0.79; 95% CI, 0.54-1.16; Wald *P* = .23).

Adjusted analysis confirmed benefit in the favorable-risk group (HR, 0.44; 95% CI, 0.24-0.82; *P* = .01) and a trended benefit in the intermediate-risk groups (HR, 0.75; 95% CI, 0.55-1.03; *P* = .08).

Table 1. Median OS and HRs for death by treatment (HD vs SD), according to subgroup

Subgroup	Standard dose (45 mg/m ² per day)			High dose (90 mg/m ² per day)			Univariate			Multivariable*			
	CR rate	Median OS (months) (no. of events/total)	4-year OS	CR rate	Median OS (months) (no. of events/total)	4-year OS	Fisher's exact P	Log-rank P	HR (95% CI)	Wald P	No. of events/total	HR (95% CI)	Wald P
All patients	59%	16.6 (246/330)	31%	71%	25.4 (207/327)	39%	.001	.001	0.74 (0.61, 0.89)	0.001	450/653	0.74 (0.61, 0.89)	.001
Age													
<50 years	61%	20.7 (133/188)	35%	73%	44.7 (96/172)	48%	.02	.002	0.66 (0.50, 0.85)	0.002	228/359	0.67 (0.52, 0.88)	.004
≥50 years	56%	12.6 (113/142)	25%	68%	17.6 (111/155)	28%	.03	.12	0.81 (0.62, 1.06)	0.12	222/294	0.82 (0.63, 1.07)	.14
Cytogenetic													
Favorable	84%	39.4 (24/38)	46%	80%	NR (19/51)	64%	.78	.02	0.51 (0.28, 0.93)	0.03	43/89	0.44 (0.24, 0.82)	.01
Intermediate	56%	20.1 (101/141)	35%	77%	33.5 (71/127)	45%	.0003	.01	0.68 (0.50, 0.92)	0.01	172/267	0.75 (0.55, 1.03)	.08
Indeterminate	62%	14.3 (66/91)	29%	67%	21.3 (62/85)	29%	.53	.47	0.88 (0.62, 1.24)	0.47	127/175	0.89 (0.63, 1.27)	.53
Unfavorable	44%	10.2 (54/59)	14%	57%	10.6 (54/63)	19%	.20	.22	0.79 (0.54, 1.16)	0.23	108/122	0.66 (0.44, 0.98)	.04
Gene mutation													
<i>NPM1</i>	60%	16.9 (50/65)	29%	89%	75.9 (31/65)	52%	.0002	.002	0.50 (0.32, 0.78)	0.002	81/130	0.51 (0.32, 0.81)	.005
<i>FLT3-ITD</i>	48%	10.1 (74/83)	17%	70%	15.2 (44/64)	28%	.008	.009	0.61 (0.42, 0.89)	0.009	117/146	0.50 (0.32, 0.77)	.002
<i>DNMT3A</i>	61%	14.1 (55/61)	13%	79%	16.5 (40/56)	33%	.03	.02	0.62 (0.41, 0.94)	0.02	95/118	0.67 (0.42, 1.05)	.08
<i>MLL-PTD</i>	56%	16.2 (16/16)	6%	60%	20.6 (10/15)	33%	1.00	.056	0.46 (0.21, 1.04)	0.06	26/30	0.60 (0.24, 1.54)	.29

NR, not reached.
*Adjusted for sex, age, hemoglobin level, leukocyte count, platelet count, and cytogenetics.

Additionally, we now demonstrated a benefit in patients in the unfavorable-risk group (HR, 0.66; 95% CI, 0.44-0.98; Wald *P* = .04; Table 1). In summary, with longer follow-up, the benefit of HD daunorubicin is shown to extend to patients with favorable cytogenetics, in addition to intermediate cytogenetic risk on univariate analysis, with adjusted analysis supporting these conclusions. A benefit for patients with unfavorable cytogenetic risk is suggested after controlling for other confounding factors.

Impact of HD daunorubicin on patients with *FLT3-ITD*, *NPM1*, or *DNMT3A* mutant AML, including older patients

We examined the benefit of HD daunorubicin in AML subgroups defined by gene mutations. We focused on previously examined groups (*FLT3-ITD* or *MLL-PTD*) and the 2 other most commonly mutant genes in our cohort: *NPM1* (26%) and *DNMT3A* (24%). Details of analysis of gene data have been reported previously; the number of patients with other gene mutations together with the HR for death based on the updated survival data are shown in supplemental Figure 3.^{17,18}

Patients with *FLT3-ITD* mutant AML benefited similarly from HD daunorubicin as patients with *FLT3-ITD* wild-type AML (*FLT3-ITD* mutant: HR, 0.61; 95% CI, 0.42-0.89; Wald *P* = .009; *FLT3-ITD* wild type: HR, 0.74; 95% CI, 0.59-0.92; Wald *P* = .008; Wald *P* for interaction = .35). Among patients with *FLT3-ITD* mutant AML, those assigned to HD daunorubicin had a median OS of 15.2 months compared with 10.1 months in the SD group. Additionally 4-year OS was 28% in the HD group compared with 17% in the SD group, suggesting that an additional 10% of *FLT3-ITD* mutant patients can be cured with HD daunorubicin (Figure 1A; Table 1).

Patients with *DNMT3A* mutant AML also benefited from HD daunorubicin, with the magnitude of benefit similar to patients with wild-type *DNMT3A* (*DNMT3A* mutant: HR, 0.62; 95% CI, 0.41-0.94; Wald *P* = .02; *DNMT3A* wild type: HR, 0.66; 95% CI, 0.52-0.85; Wald *P* = .001; Wald *P* for interaction = .79). Among *DNMT3A* mutant patients, median OS was longer in those receiving HD therapy compared with SD therapy (16.5 vs 14.1 months), with the proportion of patients alive at 4 years higher in the HD group (33%) compared with the SD group (13%; Figure 1B).

Finally, although patients with and without *NPM1* mutations benefited from HD therapy, those with an *NPM1* mutation derived more benefit (*NPM1* wild type: HR, 0.70; 95% CI, 0.55-0.89; *P* = .003; *NPM1* mutant: HR, 0.50; 95% CI, 0.32-0.78; Wald *P* = .002; Wald *P* for interaction = .17). Incredibly, patients with *NPM1* mutant AML exposed to HD daunorubicin derived a 59-month increase in median OS (16.9- and 75.9-month median OS, respectively, for *NPM1* mutant patients receiving SD and HD therapy) and an increase in 4-year OS from 29% to 52% (Figure 1C).

The rate of CR was also improved with HD therapy in patients with *NPM1*, *DNMT3A*, or *FLT3-ITD* mutant AML (Table 1). In sum, HD daunorubicin was shown in univariate analysis to benefit patients with mutant *NPM1*, *DNMT3A*, or *FLT3-ITD*; benefit was similar on adjusted analysis (Table 1). Only 31 patients had the *MLL-PTD* mutation, and no significant CR or OS benefit was observed.

We also examined the benefit of HD daunorubicin for *NPM1*, *DNMT3A*, *FLT3-ITD*, and *MLL-PTD* mutant AML separately within the younger (<50 years) and older (≥50-60 years) age strata. Patients under age 50 with *NPM1* or *DNMT3A* mutant AML benefited from HD daunorubicin (univariate and adjusted analysis); benefit was demonstrated for younger patients with *FLT3-ITD* and *MLL-PTD* on adjusted analysis (top section, supplemental Table 1). In contrast, patients ≥50 years with *NPM1* or *FLT3-ITD* mutant AML benefited from HD




Figure 1. Kaplan-Meier curves of *FLT3*-ITD, *DNMT3A*, and *NPM1* mutant AML, by treatment assignment. Data for overall survival from the intention-to-treat analysis are shown for patients with (A) *FLT3*-ITD, (B) *DNMT3A*, and (C) *NPM1* mutant AML according to assignment to SD daunorubicin (45 mg/m² per day) or HD daunorubicin (90 mg/m² per day).

daunorubicin, but the benefit was nonsignificant for older patients with *DNMT3A* or *MLL-PTD* mutations (middle section, supplemental Table 1).

Additionally, when restricting to patients with intermediate cytogenetics, the benefit of HD daunorubicin for patients with *NPM1*, *FLT3*-ITD, and *DNMT3A* mutant AML was confirmed in the univariate




Figure 2. HD daunorubicin is necessary for benefit of the *NPM1* mutation. Data for overall survival from the intention-to-treat analysis are shown for patients with *NPM1* mutant and *NPM1* wild-type AML by receipt of HD daunorubicin or SD daunorubicin.

Table 2. Median EFS and HRs by treatment (HD vs SD), according to subgroup

Subgroup	Standard dose (45 mg/m ² per day)			High dose (90 mg/m ² per day)			Univariate			Multivariable†			
	4-year cum rips rate*	Median EFS (months) (no. of events/total)	4-year EFS	4-y Cum Rips Rate	Median EFS (months) (no. of events/total)	4-year EFS	P for rips†	Log-rank P for EFS	HR (95% CI)	Wald P	No. of events/total	HR (95% CI)	Wald P
All patients	57%	4.5 (272/330)	20%	55%	11.3 (235/327)	28%	.26	<.0001	0.71 (0.60, 0.85)	.0001	503/650	0.70 (0.59, 0.84)	<.0001
Age													
<50 years	58%	5.0 (152/188)	20%	51%	13.9 (112/172)	36%	.06	<.0001	0.62 (0.48, 0.79)	.0001	263/359	0.63 (0.49, 0.82)	.0004
≥50 years	54%	4.0 (120/142)	19%	58%	9.4 (123/155)	19%	.70	.15	0.83 (0.65, 1.07)	.15	240/294	0.83 (0.64, 1.08)	.16
Cytogenetic													
Favorable	54%	14.0 (25/38)	36%	39%	17.2 (28/51)	44%	.21	.33	0.77 (0.45, 1.32)	.34	53/89	0.75 (0.42, 1.31)	.31
Intermediate	56%	3.7 (116/141)	20%	55%	16.1 (84/127)	33%	.22	.0002	0.59 (0.44, 0.78)	.0002	199/267	0.63 (0.47, 0.84)	.002
Indeterminate	59%	4.9 (74/91)	20%	69%	8.7 (69/85)	18%	.42	.55	0.91 (0.65, 1.26)	.55	142/175	0.90 (0.64, 1.26)	.53
Unfavorable	54%	0.8 (56/59)	8%	49%	4.5 (53/63)	16%	.77	.052	0.69 (0.47, 1.01)	.06	109/122	0.63 (0.43, 0.93)	.02
Gene mutation													
<i>NPM1</i>	61%	4.0 (56/65)	18%	46%	21.0 (38/65)	41%	.19	<.0001	0.45 (0.30, 0.68)	.0002	94/130	0.44 (0.29, 0.69)	.0003
<i>FLT3-ITD</i>	70%	1.9 (78/83)	8%	61%	6.8 (47/64)	23%	.24	.0009	0.55 (0.38, 0.79)	.001	124/146	0.51 (0.34, 0.75)	.0007
<i>DNMT3A</i>	NA	4.4 (58/61)	5%	69%	9.4 (46/58)	21%	.84	.03	0.66 (0.45, 0.97)	.04	103/118	0.70 (0.46, 1.05)	.09
<i>MLL-PTD</i>	NA	5.2 (16/16)	0%	NA	8.7 (12/15)	20%	.81	.19	0.60 (0.28, 1.31)	.20	27/30	0.71 (0.27, 1.87)	.49

cum rips rate, cumulative relapse rate; NA, not applied due to no relapse time over 4 years on any patient in this group.

*Among patients with complete remission reported.

†Using the competing risk analysis by taking into account of death as a competing event.

‡Adjusted for sex, age, hemoglobin level, leukocyte count, platelet count, and cytogenetics.

analysis. The multivariable analysis supports the dose effect on *NPM1* and a trended dose effect on *DNMT3A* (bottom section, supplemental Table 1).

Based on previous reports demonstrating that the prognostic impact of *NPM1* and *FLT3-ITD* is not independent,^{18,25,26} we examined the benefit of HD daunorubicin in *NPM1* and *FLT3-ITD* mutant patients considering mutations in the other gene. We confirmed in the multivariable analysis that the benefit of HD daunorubicin in *NPM1* mutant patients exists regardless of *FLT3-ITD* mutant status (*FLT3-ITD* mutant: HR, 0.54; 95% CI, 0.27-1.08; Wald *P* = .08; *FLT3-ITD* wild type: HR, 0.45; 95% CI, 0.22-0.94; Wald *P* = .03; supplemental Table 2). We also assessed the impact of HD daunorubicin in *NPM1* wild-type patients by *FLT3-ITD* status. We found significant benefit of HD daunorubicin in *NPM1* wild-type patients exists for *FLT3-ITD* wild-type patients (HR, 0.69; 95% CI, 0.52-0.91; Wald *P* = .009) in the adjusted analysis. No statistically significant dose benefit was observed in *NPM1* wild-type patients with *FLT3-ITD* mutation (HR, 0.69; 95% CI, 0.38-1.27; Wald *P* = .23). Of note, within the *FLT3-ITD* mutant subgroup, a test of interaction between treatment and *NPM1* status was not significant (adjusted *P* = .27), indicating that the benefit of HD daunorubicin in *FLT3-ITD* mutant does not require concurrent *NPM1* mutation.

Additionally, we assessed the benefit of HD daunorubicin in patients with *IDH* mutations given a previous report suggesting favorable prognosis in patients with *NPM1*⁺/*FLT3-ITD*⁻/*IDH*⁺ AML.¹⁸ Patients with *IDH*⁺ AML (n = 83) benefited from HD daunorubicin (HR, 0.58; 95% CI, 0.33-0.99; Wald *P* = .047); multivariable analysis confirmed benefit (HR, 0.56; 95% CI, 0.30-1.04; Wald *P* = .067). In the small subgroup of *NPM1*⁺/*FLT3-ITD*⁻/*IDH*⁺ patients (n = 27), a benefit was not confirmed on univariate analysis, but trended toward benefit in adjusted analysis (HR, 0.18; 95% CI, 0.03-1.24; Wald *P* = .08).

Impact of HD daunorubicin is concordant whether measured by an OS or an EFS end point

The benefit of HD daunorubicin was generally concordant whether assessed via an OS or an EFS end point (Table 2). Only patients with favorable cytogenetics demonstrated an OS benefit that was not confirmed in the EFS analysis (HR, 0.77; 95% CI, 0.45-1.32; Wald *P* = .34). Benefit of HD daunorubicin for patients with intermediate cytogenetics and for patients with *NPM1*, *FLT3-ITD*, and *DNMT3A* mutant AML was confirmed using an EFS end point.

HD daunorubicin is required for the favorable impact of *NPM1* mutation

NPM1 mutant AML is associated with a favorable outcome compared with *NPM1* wild-type AML.²⁷ However, we found that the favorable impact of an *NPM1* mutation depended on treatment assignment, although the interaction between the treatment assignment and the *NPM1* mutation status was not significant (*P* = .17). In the HD group, the HR for death of *NPM1* mutant AML compared with *NPM1* wild-type AML was 0.60 (95% CI, 0.41-0.89; Wald *P* = .01), with *NPM1* mutant patients having a median OS of 75.9 months (4-year OS, 52%) compared with 23.3 months in the wild-type group (4-year OS, 34%). In contrast, for the SD group, the HR for death (mutant/wild type) was not significant (HR, 0.84; 95% CI, 0.61-1.16; Wald *P* = .30; Figure 2), with median OS of 16.9 and 14.2 months for the mutant group and the wild-type group, respectively (log-rank *P* = .30). After adjusting for other prognostic factors plus *FLT3-ITD*, *MLL-PTD*, and *DNMT3A*, the prognostic

Table 3. HRs (mutant/wild type) for death, according to treatment dose and gene

Gene	Mutant			Wildtype			Univariate			Multivariable*		
	Median OS (months) (no. of events/total)	4-year OS	4-year OS	Median OS (months) (no. of events/total)	4-year OS	4-year OS	Log-rank P	HR (95% CI)	Wald P	No. of events/total	HR (95% CI)	Wald P
Main effect												
<i>NPM1</i>	23.5 (81/130)	40%	29%	16.9 (279/372)	29%	29%	.01	0.73 (0.57, 0.94)	.01		0.68 (0.50, 0.92)	.01
<i>FLT3-ITD</i>	11.7 (118/147)	22%	38%	25.0 (303/456)	38%	38%	<.0001	1.65 (1.33, 2.04)	<.0001	338/477	1.67 (1.28, 2.19)	.0002
<i>DNMT3A</i>	15.3 (95/119)	23%	36%	22.8 (254/371)	36%	36%	.03	1.31 (1.03, 1.66)	.03	338/477	1.54 (1.18, 2.01)	.002
<i>MLL-PTD</i>	16.9 (26/31)	19%	35%	21.0 (405/586)	35%	35%	.13	1.36 (0.92, 2.03)	.13	338/477	0.80 (0.49, 1.30)	.36
Standard dose												
<i>NPM1</i>	16.9 (50/65)	29%	24%	14.2 (148/180)	24%	24%	.30	0.84 (0.61, 1.16)	.30	186/232	0.93 (0.63, 1.38)	.71
<i>FLT3-ITD</i>	10.1 (74/83)	17%	34%	20.3 (156/215)	34%	34%	<.0001	1.77 (1.34, 2.33)	<.0001	186/232	2.10 (1.45, 3.05)	<.0001
<i>DNMT3A</i>	14.1 (55/61)	13%	30%	16.1 (137/177)	30%	30%	.06	1.35 (0.98, 1.85)	.06	186/232	1.47 (1.03, 2.10)	.04
<i>MLL-PTD</i>	16.2 (16/16)	6%	30%	16.5 (220/290)	30%	30%	.08	1.58 (0.95, 2.63)	.08	186/232	1.01 (0.54, 1.90)	.98
High dose												
<i>NPM1</i>	75.9 (31/65)	52%	34%	23.3 (131/192)	34%	34%	.01	0.60 (0.41, 0.89)	.01	152/245	0.48 (0.30, 0.78)	.003
<i>FLT3-ITD</i>	15.2 (44/64)	28%	42%	31.7 (147/241)	42%	42%	.04	1.43 (1.02, 2.01)	.04	152/245	1.35 (0.89, 2.04)	.16
<i>DNMT3A</i>	16.5 (40/58)	33%	41%	29.2 (117/194)	41%	41%	.23	1.25 (0.87, 1.79)	.23	152/245	1.51 (0.99, 2.31)	.06
<i>MLL-PTD</i>	20.6 (10/15)	33%	40%	27.4 (185/296)	40%	40%	.68	1.14 (0.61, 2.16)	.68	152/245	0.61 (0.27, 1.36)	.23

*Sex, age, hemoglobin level, leukocyte count, platelet count, cytogenetics, and all 4 genes were fitted into the model.

impact of *NPM1* was even stronger in the HD group (the HD group: HR [mutant/wild type] = 0.48; 95% CI, 0.30-0.78; Wald *P* = .003; the SD group: HR = 0.93, 95% CI, 0.63-1.38; Wald *P* = .71).

In contrast to *NPM1*, the prognostic impact of *FLT3-ITD*, *MLL-PTD*, and *DNMT3A* did not depend on treatment assignment (Wald *P* values for interaction are .35, .46, and .79, respectively).

Table 3 summarizes the HRs for death for each of the target genes stratified by treatment dose. In the context of SD treatment, *FLT3-ITD* and *DNMT3A* (but not *NPM1*) contribute to the OS prediction after adjusting for other confounding factors in the model. In contrast, in the setting of HD treatment, *NPM1* and *DNMT3A* (but not *FLT3-ITD*) contribute to OS prediction after adjusting for other confounding factors.

Effect of molecular mutation on benefit of gemtuzumab

Of 307 patients registered to autologous HCT, 153 (49.8%) received planned therapy. In an intention-to-treat analysis, we confirmed no benefit of GO overall, and no benefit was seen in any age or cytogenetic strata except that patients with intermediate cytogenetics had inferior OS if they were assigned to receive GO (supplemental Table 3). Additionally, there was no GO benefit in patients with *NPM1*, *DNMT3A*, *FLT3-ITD*, or *MLL-PTD* mutant AML. Results were similar when analysis was restricted to patients who actually received autologous transplant, although the unfavorable impact of GO on patients with intermediate cytogenetics was no longer seen (supplemental Table 4).

Discussion

Many factors impact survival after an AML diagnosis including patient characteristics, disease characteristics, and therapy received. Although patient and disease characteristics are typically immutable, modification of the therapy administered has the potential to improve outcomes. Here, we present updated results of the E1900 trial and demonstrate the broad ability of anthracycline intensification during induction to improve OS in patients age 60 or younger with de novo AML, including those with favorable and intermediate cytogenetics and those with mutations in *FLT3-ITD*, *NPM1*, and *DNMT3A*. A benefit in those with unfavorable cytogenetic risk is suggested on multivariable analysis; however, a larger study focused on this patient population would be needed to confirm the benefit.

The ECOG-ACRIN study, E1900, joins a series of studies attempting to improve the anthracycline plus cytarabine regimen that has long been a standard for AML induction in younger patients.^{1,2} At the time of study initiation, all previous attempts to improve OS with the addition of a third drug or by increasing the dose of cytarabine had been unsuccessful (although since the initial publication of E1900, an OS benefit of gemtuzumab ozogamicin, cladribine, and HD cytarabine has been demonstrated in subgroups).^{1,3-12} E1900 studied whether an increased dose of daunorubicin used during induction could increase rates of remission and, more importantly, improve OS. The results of E1900 reported in 2009 confirmed the benefit of anthracycline intensification in younger patients in AML: an exciting and long-awaited improvement in a decades-old regimen.^{1,2} The results were additionally significant because HD daunorubicin was not associated with additional toxicity, obviating difficult discussions about benefit vs potential morbidity. The benefit of HD daunorubicin has since been confirmed prospectively in both younger²⁸ and older patients,²⁹ as well as by a retrospective meta-analysis.³⁰

The celebration of the original results was tempered by the determination that not all subgroups benefited; in particular, patients with high-risk features such as older age (age ≥ 50 years), unfavorable cytogenetics, and *FLT3*-ITD mutant AML did not appear to derive benefit.¹⁷ However, we continued to follow patients, and mature data now suggest broader benefit in high-risk patients: patients with unfavorable cytogenetics were shown to benefit in multivariable analysis (suggesting need for further study and confirmation) and benefit was confirmed on both univariate and multivariable analysis for those with *FLT3*-ITD mutant AML. The 4-year OS (which is arguably a surrogate for cure) is 10% higher in the patients with *FLT3*-ITD mutant AML receiving HD therapy.

We also demonstrate a benefit for HD daunorubicin in patients with *NPM1* and *DNMT3A* mutant AML, with a particularly marked advantage seen in patients with *NPM1* mutant AML. *NPM1* mutant patients receiving HD daunorubicin had a remarkable increase in median OS (75.9 vs 16.9 months) and a $>20\%$ increase in 4-year OS (52% vs 29%), indicating that HD daunorubicin offers a meaningful increase in OS (and likely cure) to the approximately one-fourth of AML patients who carry an *NPM1* mutation, regardless of *FLT3*-ITD status.

The findings in the *NPM1* mutant group were additionally significant because we demonstrate that the known prognostic impact of *NPM1* depended on treatment assignment, an effect that persisted after adjusting for other prognostic factors and common co-occurring mutations (*FLT3*-ITD and *DNMT3A*).²⁷ This highlights the importance of interpreting prognostic studies in the context of the specific treatment received. Indeed, after adjustment, we found that *FLT3*-ITD was only prognostic in the setting of SD treatment, whereas *DNMT3A* was prognostic regardless of daunorubicin dose. Additionally, our updated analysis confirms that, although patients aged 50 to 60 years do not benefit overall, a substantial subgroup of older patients with *NPM1* or *FLT3*-ITD mutant AML do benefit from HD daunorubicin. Finally, we show that the benefit of HD daunorubicin as measured by OS is largely concordant to conclusions drawn by analysis of an EFS end point, suggesting that EFS may be a reliable end point in AML clinical trials.

In contrast to our study, the UK AML17 trial comparing 90 to 60 mg/m² of daunorubicin during the first induction course for untreated AML has reported excess early mortality without improvement in OS. It is important to recognize the significant differences in induction strategy and cumulative anthracycline dose between E1900 and UK AML 17. In E1900, only patients with residual leukemic blasts at nadir marrow assessment received a second course of induction such that only patients positioned to benefit were exposed to additional toxicity (38% of those who ultimately achieved CR received a second cycle). In contrast, in UK AML 17, a second course of induction including 50 mg/m² per day of daunorubicin for 3 days was given regardless of response to first induction; this approach may have led to overtreatment and excess toxicity in the cohort that negated any OS benefit. In addition, the standard arm in UK AML 17 received a cumulative dose of 110 mg/m² of daunorubicin; this dose exceeds the dose that the majority of patients assigned to the HD arm in E1900 received. In essence, both arms of UK AML 17 received HD daunorubicin by E1900 definition, and the UK AML 17 investigators demonstrated that further dose escalation (via a standard second induction course for a cumulative daunorubicin dose of 140 mg/m² in the HD arm) did not provide further benefit.²⁵

We additionally present results regarding the impact of HD daunorubicin on OS for a larger group of gene mutations; these results,

however, need to be interpreted with caution due to the rarity of mutation incidences. Further study is required to confirm the impact of daunorubicin dose on these subgroups. We also lack data on *FLT3*-ITD allelic ratio, and therefore the impact of this variable on the benefit of HD daunorubicin in the *FLT3*-ITD subgroup will require further investigation.

With longer follow-up, we were still unable to confirm a benefit of HD daunorubicin in older patients (aged 50-60 years), whereas Lowenberg et al²⁹ demonstrated a significant improvement in OS in patients aged 60 to 65 years receiving HD daunorubicin. The reason for this discrepancy is not entirely clear, although the administration of HD daunorubicin in Lowenberg et al was in the context of a higher dose of cytarabine (200 mg/m² per day for 7 days), and additionally, all patients received a second cycle of chemotherapy (cytarabine) without additional daunorubicin.

In sum, in this updated analysis of the E1900 trial, we demonstrate that HD daunorubicin benefits AML patients with *FLT3*-ITD mutations, may benefit patients with unfavorable cytogenetics, and additionally demonstrates benefit in a significant subgroup of older patients aged 50 to 60 years with *FLT3*-ITD or *NPM1* mutations. We also demonstrate that *NPM1* mutant patients particularly benefit from HD therapy and that the favorable prognosis associated with presence of an *NPM1* is uniquely associated with higher-dose therapy.

With demonstration of the expanded benefit of HD daunorubicin, we suggest that HD daunorubicin be the standard for all eligible adult patients up to 60 years of age and be the standard of comparison for future clinical trials. Additionally, as we enter an era of targeted therapy, including for *FLT3*-ITD mutant AML in the upfront setting,³¹ it is important that these agents be tested in the context of optimal chemotherapy.

Acknowledgments

This study was conducted by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD, and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA180867, CA180791, CA180790, CA180583, and CA189859, the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.

This study's content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute

Authorship

Contribution: M. R. Luskin, S.M.L., J.-W.L., and Z.S. designed the analysis and wrote the manuscript; H.F.F., H.M.L., M.R.L., J.R., M.S.T., and S.M.L. provided patients; M. R. Luskin, S.M.L., J.-W.L., Z.S., H.F.F., O.A.-W., J.M.B., R.P.K., H.M.L., R.L.L., M. R. Litzow, E.M.P., J.P.P., J.R., J.M.R., and M.S.T. analyzed and interpreted data and reviewed the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Selina Luger, Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104; e-mail: selina.luger@uphs.upenn.edu.

References

- Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. *Cancer Chemother Rep*. 1973;57(4):485-488.
- Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. *Blood*. 1982;60(2):454-462.
- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. *J Clin Oncol*. 2012;30(20):2441-2448.
- Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*. 2014;15(9):986-996.
- Willemze R, Suci S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J Clin Oncol*. 2014;32(3):219-228.
- Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. *Leuk Lymphoma*. 1998;28(3-4):315-327.
- Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. *Br J Haematol*. 1992;81(2):170-177.
- Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. *Blood*. 1996;88(8):2841-2851.
- Bishop JF, Lowenthal RM, Joshua D, et al; Australian Leukemia Study Group. Etoposide in acute nonlymphocytic leukemia. *Blood*. 1990;75(1):27-32.
- Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. *Blood*. 1991;78(10):2520-2526.
- Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. *Blood*. 1987;69(5):1441-1449.
- Schiller G, Nimer S, Gajewski J, et al. Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study. *Leuk Lymphoma*. 1993;11(1-2):69-77.
- Appelbaum FR, Dahlberg S, Thomas ED, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. *Ann Intern Med*. 1984;101(5):581-588.
- Büchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. *J Clin Oncol*. 1985;3(12):1583-1589.
- Rowe JM, Tallman MS. Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? *Blood*. 1997;90(6):2121-2126.
- Kolitz JE, George SL, Dodge RK, et al; Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. *J Clin Oncol*. 2004;22(21):4290-4301.
- Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009;361(13):1249-1259.
- Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1079-1089.
- Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
- Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. *Blood*. 2000;96(13):4075-4083.
- Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. *Leukemia*. 2002;16(11):2185-2189.
- Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. *Leukemia*. 2000;14(5):796-804.
- Fernandez HF, Sun Z, Litzow MR, et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*. 2011;117(20):5306-5313.
- Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16(3):1141-1154.
- Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. *Blood*. 2005;106(12):3740-3746.
- Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. *Blood*. 2008;111(5):2776-2784.
- Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-1918.
- Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood*. 2011;118(14):3832-3841.
- Löwenberg B, Ossenkoppele GJ, van Putten W, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med*. 2009;361(13):1235-1248.
- Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. *Br J Haematol*. 2013;161(2):192-203.
- Stone RM, Sumithra M, Sanford BL, et al. The multi-kinase inhibitor midostaurin prolongs survival compared with placebo in combination with daunorubicin/cytarabine induction, high-dose consolidation, and as maintenance therapy in newly diagnosed acute myeloid leukemia patients age 18-60 with FLT3 mutations: an international prospective randomized placebo-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) [abstract]. *Blood*. 2015;126(23):Abstract 6.